SCHEMBL2326581

SCHEMBL2326581

COc1ccc(Cl)c(NC(=O)N(C)c2cc(Nc3cccc(C(=O)N4CCN(C)CC4)c3)ncn2)c1Cl

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR3 P22607 12/20 0.72
CYP3A4 P08684 6/20 0.68
CYP2C19 P33261 5/20 0.68
CYP2C9 P11712 2/20 0.68
CYP1A2 P05177 1/20 0.65
FGFR1 P11362 5/20 0.62
LCK P06239 7/20 0.58
JAK2 O60674 2/20 0.52
ABL1 P00519 2/20 0.52
INSR P06213 2/20 0.52
FYN P06241 2/20 0.52
YES1 P07947 2/20 0.52
LYN P07948 2/20 0.52
RET P07949 2/20 0.52
MET P08581 2/20 0.52
ROS1 P08922 2/20 0.52
KIT P10721 2/20 0.52
SRC P12931 2/20 0.52
BRAF P15056 2/20 0.52
PDGFRA P16234 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL374601 0.92 FGFR3 (0.80) FGFR3CYP3A4CYP2C19CYP2C9CYP1A2
SCHEMBL374211 0.88 FGFR3 (0.87) FGFR3CYP3A4CYP2C19CYP2C9CYP1A2
SCHEMBL581714 0.84 FGFR1 (0.74) FGFR3CYP3A4CYP2C19CYP2C9CYP1A2
SCHEMBL374547 0.84 FGFR3 (1.00) FGFR3CYP3A4CYP2C19CYP2C9CYP1A2
SCHEMBL374757 0.82 FGFR3 (0.80) FGFR3CYP3A4CYP2C19CYP2C9CYP1A2
SCHEMBL374711 0.81 FGFR3 (1.00) FGFR3CYP3A4CYP2C19CYP2C9CYP1A2
SCHEMBL19732275 0.79 FGFR1 (0.84) FGFR3CYP3A4CYP2C19CYP2C9CYP1A2
SCHEMBL2013490 0.79 FGFR3 (1.00) FGFR3CYP3A4CYP2C19CYP2C9CYP1A2
SCHEMBL582750 0.77 FGFR3 (0.80) FGFR3CYP3A4CYP2C19CYP2C9CYP1A2
SCHEMBL16659469 0.77 FGFR1 (1.00) FGFR3FGFR1FGFR2FGFR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1761505-B1 PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS NOVARTIS AG (CH) 2011-08-17 EP disclosed